Table 2.
Pharmacokinetic parameters of ERT after intravenous administration of free ERT, ERT-HSA NPs, and ERT-HSA-HA NPs to rats
| Parameters | Intravenous administration
|
||
|---|---|---|---|
| Free ERT | ERT-HSA NPs | ERT-HSA-HA NPs | |
| t½ (min) | 38.3±7.2 | 91.2±7.9* | 96.4±8.3* |
| AUC0–t (µg⋅min/mL) | 129.1±12.3 | 391.5±34.3* | 496.2±45.3* |
| AUC0–∞ (µg⋅min/mL) | 143.6±15.3 | 432.3±47.2* | 546.3±49.8* |
| MRT (min) | 26.4±3.9 | 69.3±7.2* | 78.3±9.1* |
| CL (L/kg/min) | 0.32±0.12 | 0.09±0.02* | 0.08±0.03* |
Notes:
*
P<0.05 vs free ERT; n=6.
Abbreviations: ERT, erlotinib; ERT-HSA NPs, human serum albumin-modified erlotinib nanoparticles; ERT-HSA-HA NPs, hyaluronic acid- and human serum albumin-modified erlotinib nanoparticles; t½, half-life; AUC, area under the curve; MRT, mean residence time; CL, clearance.